{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=radioactive+drug+%28tracer%29&page=2", "query": { "intervention": "radioactive drug (tracer)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 119, "total_pages": 12, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=radioactive+drug+%28tracer%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=radioactive+drug+%28tracer%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T05:01:58.940Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03746847", "title": "PET Imaging in Patients With Suspected Cardiac Sarcoidosis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cardiac Sarcoidosis" ], "interventions": [ { "name": "Gallium-68 DOTATATE", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2018-12-01", "completion_date": "2022-12-01", "has_results": false, "last_update_posted_date": "2022-12-14", "last_synced_at": "2026-10-08T05:01:58.940Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03746847" }, { "nct_id": "NCT05595460", "title": "Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "SCLC,Extensive Stage" ], "interventions": [ { "name": "RYZ101 Dose Level -1", "type": "DRUG" }, { "name": "RYZ101 Dose Level 2", "type": "DRUG" }, { "name": "RYZ101 Dose Level 3", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "RayzeBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2022-10-10", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-10-08T05:01:58.940Z", "location_count": 12, "location_summary": "Los Angeles, California • San Francisco, California • Jacksonville, Florida + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05595460" }, { "nct_id": "NCT06531499", "title": "A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer" ], "interventions": [ { "name": "AAA617", "type": "DRUG" }, { "name": "Gonadotropin-releasing hormone (GnRH) analogues", "type": "DRUG" }, { "name": "Gonadotropin-releasing hormone (GnRH) antagonists", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 106, "start_date": "2024-11-11", "completion_date": "2028-11-24", "has_results": false, "last_update_posted_date": "2025-12-31", "last_synced_at": "2026-10-08T05:01:58.940Z", "location_count": 5, "location_summary": "Los Angeles, California • Palo Alto, California • Rochester, Minnesota + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06531499" }, { "nct_id": "NCT00597246", "title": "Imaging Brain Tumors With FACBC and Methionine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Brain Cancer", "CNS Cancer" ], "interventions": [ { "name": "FACBC, Methionine", "type": "DRUG" }, { "name": "PET Scan", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 30, "start_date": "2003-05-13", "completion_date": "2019-11-27", "has_results": true, "last_update_posted_date": "2020-12-17", "last_synced_at": "2026-10-08T05:01:58.940Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00597246" }, { "nct_id": "NCT03699644", "title": "Multimodal Ocular Imaging in Neurodegeneration", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Alzheimer Disease", "Alzheimer Dementia", "Frontotemporal Dementia" ], "interventions": [ { "name": "Spectral-Domain Optical Coherence Tomography (SD-OCT)", "type": "DEVICE" }, { "name": "Magnetic Resonance Imaging (MRI)", "type": "DEVICE" }, { "name": "Positron Emission Tomography (PET)", "type": "DEVICE" }, { "name": "Comprehensive Ophthalmic Examination", "type": "DIAGNOSTIC_TEST" }, { "name": "Fundus Photography", "type": "DEVICE" } ], "intervention_types": [ "DEVICE", "DIAGNOSTIC_TEST" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "45 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "45 Years to 80 Years" }, "enrollment_count": 16, "start_date": "2019-01-04", "completion_date": "2019-04-03", "has_results": false, "last_update_posted_date": "2022-03-28", "last_synced_at": "2026-10-08T05:01:58.940Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03699644" }, { "nct_id": "NCT07781852", "title": "Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Bladder Cancer", "Glioma", "Glioblastoma (GBM)", "Breast Cancer", "Colorectal Cancer", "Esophageal Cancer", "Gastric Cancer (GC)", "Pharynx Cancer", "Oral Cavity Cancer", "Kidney Cancer", "Liver Cancer", "Lung Cancer (NSCLC)", "Ovarian Cancer", "Pancreatic Cancer", "PDAC - Pancreatic Ductal Adenocarcinoma", "Prostate Cancer" ], "interventions": [ { "name": "[64Cu]CM500", "type": "DRUG" }, { "name": "[68Ga]CM500", "type": "DRUG" }, { "name": "PET/MR", "type": "DEVICE" }, { "name": "PET/CT", "type": "DEVICE" }, { "name": "Blood Collection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "DEVICE", "PROCEDURE" ], "sponsor": "Lumina Pharmaceuticals Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2026-09-01", "completion_date": "2027-09-01", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-08T05:01:58.940Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Grand Rapids, Michigan • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07781852" }, { "nct_id": "NCT01975636", "title": "An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metabolism and Elimination" ], "interventions": [ { "name": "E2609", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 113, "start_date": "2013-06", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2016-01-08", "last_synced_at": "2026-10-08T05:01:58.940Z", "location_count": 2, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01975636" }, { "nct_id": "NCT03030885", "title": "Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer", "Metastatic Castration-Resistant Prostate Cancer (mCRPC)" ], "interventions": [ { "name": "131I-MIP-1095", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 10, "start_date": "2017-01-19", "completion_date": "2019-04-02", "has_results": false, "last_update_posted_date": "2019-04-05", "last_synced_at": "2026-10-08T05:01:58.940Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03030885" }, { "nct_id": "NCT05908773", "title": "A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "TTX-MC138-NODAGA-Cu64", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TransCode Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 1, "start_date": "2023-04-04", "completion_date": "2023-09-18", "has_results": false, "last_update_posted_date": "2025-01-28", "last_synced_at": "2026-10-08T05:01:58.940Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05908773" }, { "nct_id": "NCT03673943", "title": "Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neuroendocrine Tumors" ], "interventions": [ { "name": "64Cu-DOTATATE", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Radiomedix, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2018-08-23", "completion_date": "2019-08-07", "has_results": true, "last_update_posted_date": "2022-12-22", "last_synced_at": "2026-10-08T05:01:58.940Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03673943" } ] }